Midway Immunology & Research Center
Fort Pierce, Florida, United States
Disclosure(s): AbbVie: Honoraria; Gilead Sciences, Inc: Advisor/Consultant, Honoraria; Merck: Advisor/Consultant; ViiV: Advisor/Consultant, Honoraria
577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
Saturday, October 19, 2024
2:09 PM – 2:21 PM US PT